Case Report
Primary lung mesenchymal chondrosarcoma with kidney and intermuscular metastases: a case report and literature review

Kaihu Li1, Qin Yang2, Zhengxiao Ouyang4, Fei Deng5, Beibei Gao3, Feng Zhou1, Dan Peng5

Departments of 1Orthopedics, 2Oncology, 3Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China; 4Department of Orthopedics, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China; 5Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China. *Equal contributors.

Received October 12, 2015; Accepted January 27, 2016; Epub February 15, 2016; Published February 29, 2016

Abstract: Mesenchymal chondrosarcoma (MCS) is an uncommon sarcoma which primarily occurs in the extremities but rarely originates from the lung. Herein, we report a case of a 29-year-old female who presented with a lung mass detected by the physical examination. The tumor was resected and the pathological examination revealed primary MCS of the lung. After the operation, the chemotherapy and radiotherapy were performed. However, the follow-up showed evidence of kidney and intermuscular metastases, and both of the lesions were excised with adequate margins. In addition, a review of the clinical knowledge regarding this rare disease is discussed.

Keywords: Mesenchymal chondrosarcoma, lung, immunohistochemistry, chemotherapy, radiotherapy

Introduction
MCS comprises 1-10% of all chondrosarcomas which can be divided into several subtypes including conventional, dedifferentiated, mesenchymal, and clear cell [1, 2]. First reported by Lichtenstein and Bernstein in 1959 [3], MCS is characterized histologically by the coexistence of primitive small blue mesenchymal cells and islands of differentiated cartilaginous substance [4, 5]. It has a slight female preponderance and mainly occurs in patients at age 40 or older [2]. MCS, which is most common in the bone and soft tissues, rarely originates from the lung [6, 7]. After review of the literature (online PubMed search), only 7 cases of primary MCS of the lung have been reported [5, 6, 8-12]. To the best of our knowledge, the present case of pulmonary MCS with the kidney and gluteus maximus metastases has never been reported before.

Case report
A 29-year-old woman was admitted to the Department of Cardio-Thoracic Surgery, The Second Xiangya Hospital of Central South University (Changsha, China) with a lung mass found by the routine X-ray. Computed tomography (CT) scan revealed a 6.0×5.0 cm mass with dense calcification in the upper lobe of the left lung (Figure 1). Subsequently, the intraoperative frozen section examination revealed unspecified sarcoma and the left upper lobectomy and systemic lymph nodes dissection were performed (first operation).

The resected lobe measuring 18×10×6 cm showed a well-defined reddish-gray tumor measuring 6.5×6.0 cm with scattered hard calcification areas on cut surface. Microscopically, the neoplasm was composed of undifferentiated small round tumor cells and islands of differentiated cartilaginous substance (Figure 2A). Immunohistochemistry revealed reaction to CD99 and vimentin in the small round cell areas and reaction to S-100 limited to the cartilaginous areas (Figure 2B). Besides, it was negative to cytokeratins, epithelial membranous antigen, and leukocyte common antigen. Since the comprehensive physical and image detec-
Mesenchymal chondrosarcoma and lung

The patient was referred for radiotherapy and chemotherapy. The patient recovered uneventfully and the follow-up continued every three months.

However, 21 months after the first operation, a 6×3.5 cm mass at the patient’s right kidney was detected by CT scan which resembled a malignant neoplasm (Figure 3A). Consequently, nephrectomy and lymph nodes dissection was performed (second operation). Nevertheless, the pathologic examination (Figure 4A, 4B) revealed its similarity to the pulmonary MCS resects previously, which meant it was a metastatic neoplasm from the lung.

Three years after the first operation, the patient presented to our hospital again with a mass in the right gluteus maximus for 2 months. CT scan was suggested and it demonstrated high possibility of metastasis from the lung (Figure 3B). Subsequently, the mass was resected with...
Discussion

MCS is a rare variant of chondrosarcoma and most common in the bone and soft tissues. It may occur in other sites such as the kidney, meninges, thyroid, and prostate, but rarely originates from the lung [6]. In the literature, there are only 7 cases of primary MCS of the lung (summarized in Table 1). However, pulmonary metastases of MCS from other primary sources are common [8]. Therefore, comprehensive clinical evaluation should be taken to exclude extrathoracic primary sources before the diagnosis of primary MCS of the lung, which was done in our case.

The CT may contribute to the diagnosis of MCS in the lung especially when it reveals dense and granular calcification [13, 14], but the definitive diagnosis is based on the histological results. Microscopically, the most common feature of MCS is a biphasic pattern composed of sheets of undifferentiated small round cells, as well as islets of well-differentiated cartilaginous tissue [5, 14]. Besides, immunohistochemical markers such as CD99, vimentin, and S-100 also aid the differentiation from other intrathoracic tumors characterized by small blue cells such as malignant lymphoma, small cell carcinoma, and Ewing’s sarcoma, and so forth [8].

Surgery is an optimal treatment for MCS of the lung [15], but the adjuvant therapy remains uncertain due to the paucity of reported cases [16]. However, Xu Jie et al. recommended radiation as the salvage therapy to achieve better local control for patients with positive margins [2]. Furthermore, adjuvant chemotherapy yielded excellent local control according to the cohort survey by Bishop et al. [17], which was in accordance with the retrospective study by Cesari et al. [7]. In the present case, surgery and adjuvant therapy were performed and no local recurrence have been noted so far. As for metastases, surgery is significantly associated with improved outcome [16].

In addition, some researches in new therapeutics are under way. For instance, the chemo-resistance of MCS could be overcome by using inhibition of Bcl-2 family members according to the study by van Oosterwijk et al. [18]. Other studies have investigated HEY1-NCOA2 rearrangement and expression of IDH1/2, p53, and
Table 1. Reported cases of primary MCS of the lung

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex/Age (years)</th>
<th>Presenting symptoms</th>
<th>Location</th>
<th>Size (cm)</th>
<th>Treatment</th>
<th>Immunohistochemical features</th>
<th>Follow-up (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurotaki et al. [5]</td>
<td>F/45</td>
<td>Asymptomatic</td>
<td>RLL</td>
<td>4.5×3.5×3.0</td>
<td>Lobectomy</td>
<td>Vimentin/S-100/Leu-7 (+)</td>
<td>8 (Alive with metastases)</td>
</tr>
<tr>
<td>Huang et al. [8]</td>
<td>F/40</td>
<td>Asymptomatic</td>
<td>LLL</td>
<td>6.5×4.8</td>
<td>Bisegmentectomy</td>
<td>Vimentin/S-100 (+)</td>
<td>1 (well)</td>
</tr>
<tr>
<td>Geng et al. [9]</td>
<td>M/57</td>
<td>Cough, hemoptysis</td>
<td>RLL</td>
<td>4×4×3</td>
<td>Lobectomy</td>
<td>CD99/S-100/NSE/vimentin (+)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Dubova et al. [12]</td>
<td>F/68</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>S-100/vimentin/NSE/CD99 (+)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Cao et al. [10]</td>
<td>F/45</td>
<td>Chest pain</td>
<td>RLL</td>
<td>Unknown</td>
<td>Radical thoracotomy</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Mei et al. [6]</td>
<td>F/20</td>
<td>Cough, chest pain</td>
<td>LLL</td>
<td>11.6×9.2×6.0</td>
<td>Pneumonectomy</td>
<td>vimentin/CD99/5-S-100 (+)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Present case</td>
<td>F/29</td>
<td>Asymptomatic</td>
<td>LUL</td>
<td>6.0×5.0</td>
<td>Lobectomy</td>
<td>CD99/5-S-100/vimentin (+)</td>
<td>3 (alive with metastases)</td>
</tr>
</tbody>
</table>

M, male; F, female; RLL right lower lobe; RUL left lower lobe; LLL left lower lobe; LUL left upper lobe; NSE Neuron-specific enolase.

retinoblastoma pathways which can be used as diagnostic markers but also potential for targeted therapies [1, 17].

The MCS of the bone and soft tissue has a poor prognosis, with 5-, 10-, and 20-year overall survival rates of 55.0%, 43.5%, and 15.7% respectively [2]. However, the prognosis of MCS originating from the lung remains poorly understood owing to its rarity. In the case reported by Kurotaki et al., the patient was still alive 8 years after the initial right lower lobectomy [5]. As for predictive factors, negative margins and the absence of metastases at diagnosis were reported to be significantly associated with improved overall survival [2, 7]. Furthermore, due to its strong tendency toward late local and metastatic recurrence, Frezza et al. suggested that the careful follow-up after diagnosis should last over 10 years [7].

In conclusion, the primary MCS of the lung is extremely rare and the diagnosis can only be made by excluding other primary intrathoracic sarcomas and MCS of extra thoracic sites. The surgery in conjunction with adjuvant therapy can be applied to the patient as we presented. Due to its high rate of recurrence and metastases in a long postoperative period, we suggest that long-term and frequent follow-up is needed.

Disclosure of conflict of interest

None.

Address correspondence to: Qin Yang, Department of Oncology, The Second Xiangya Hospital of Central South University, No. 139, Renmin Road, Changsha 410011, Hunan, P. R. China. E-mail: 1035693271@qq.com; Dan Peng, Department of Orthopedics, The Second Xiangya Hospital of Central South University, No. 139, Renmin Road, Changsha 410011, Hunan, P. R. China. E-mail: xyeypd@163.com

References

Mesenchymal chondrosarcoma and lung


